ERBB2 and neoplasm: The cancer immune surveillance of NK-92/5.28.z cells is triggered by the anti-ErbB2-targeted CAR and germline-encoded cell surface receptors, as well as by supporting adoptive antitumor immune responses of T cells in the TME (21), suggesting homing to, infiltration into, and persistence of NK-92/5.28.z cells at RMS tumor sites.